Histone deacetylase inhibitors: clinical implications for hematological malignancies

Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)

(2017) R. G. Bociek et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study

(2017) M. Crump et al.   JOURNAL OF CLINICAL ONCOLOGY

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

(2009) Monica Galli et al.   ANNALS OF HEMATOLOGY

Histone acetylation: truth of consequences?This paper is one of a selection of papers published in this Special Issue, entitled CSBMCB’s 51st Annual Meeting – Epigenetics and Chromatin Dynamics, and has undergone the Journal’s usual peer review process.

(2009) Jennifer K. Choi et al.   Biochemistry and Cell Biology

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

(2009) Michael Dickinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

(2009) Susan E. Bates et al.   BRITISH JOURNAL OF HAEMATOLOGY

Biomarkers for predicting clinical responses to HDAC inhibitors

(2009) Lindsay Stimson et al.   CANCER LETTERS

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Enzymes in the NAD+Salvage Pathway Regulate SIRT1 Activity at Target Gene Promoters

(2009) Tong Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis

(2009) B Stamatopoulos et al.   LEUKEMIA

Functional Connection between Deimination and Deacetylation of Histones

(2009) H. Denis et al.   MOLECULAR AND CELLULAR BIOLOGY

Expression of Hypoxia-Inducible Factor-1α, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma

(2009) Kotaro Miyake et al.   PANCREAS

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

(2008) M. Crump et al.   ANNALS OF ONCOLOGY

Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors

(2008) D.J.P. Ellis et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling

(2008) E. Bicaku et al.   CANCER RESEARCH

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

(2008) O. M. Odenike et al.   CLINICAL CANCER RESEARCH

Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics

(2008) R. Butler   CURRENT PHARMACEUTICAL DESIGN

Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead

(2008) Antonello Mai et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

(2008) Wilko Weichert et al.   LANCET ONCOLOGY

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

(2008) Paul Richardson et al.   LEUKEMIA & LYMPHOMA

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid

(2008) Anita Ryningen et al.   LEUKEMIA RESEARCH

A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73

(2008) J. M. Rosenbluth et al.   MOLECULAR AND CELLULAR BIOLOGY

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation

(2008) Yutaka Kondo et al.   NATURE GENETICS

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE

Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients

(2008) Hao-Hueng Chang et al.   ORAL ONCOLOGY

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas

(2008) Omar Khan et al.   Nature clinical practice. Oncology